公开(公告)号：US20230346821A1

公开(公告)日：2023-11-02

申请号：US18203828

申请日：2023-05-31

申请人： LEMONEX INC.

发明人： Cheol Hee WON ,  Jun KIM

IPC分类号： A61K31/7105 ,  A61K47/69 ,  A61K47/54 ,  A61K31/713 ,  A61P35/00

CPC分类号： A61K31/7105 ,  A61K31/713 ,  A61K47/549 ,  A61K47/6923 ,  A61P35/00 ,  B82Y5/00

摘要： A nucleic acid carrier according to an embodiment of the present disclosure includes CpG-ODN-RNA conjugate and a porous silica particle carrying the conjugate inside pores thereof. In this regard, the nucleic acid carrier of the present invention can stably deliver loaded nucleic acid molecules to a body and release the same to a target, thereby increasing Type 1 interferon and exhibiting RNA-inherent functions.

公开(公告)号：US20220280602A1

公开(公告)日：2022-09-08

申请号：US17630419

申请日：2020-07-31

申请人： LEMONEX INC.

发明人： Cheol Hee WON

IPC分类号： A61K38/17 ,  A61K9/16 ,  A61P35/00 ,  A61K47/69

摘要： An anticancer drug according to an embodiment of the present disclosure includes porous silica particles having an anticancer active peptide incorporated therein. Nitrogen-containing groups are located on an outer surface of each porous silica particle, and folic acid is bound to at least some of the nitrogen-containing groups, whereby the anticancer drug has an excellent target delivery ability, is of high stability without forming a precipitate in an in-vivo environment, and is applicable to various carcinomas.

公开(公告)号：US20210093654A1

公开(公告)日：2021-04-01

申请号：US16634675

申请日：2018-07-30

申请人： LEMONEX INC.

发明人： Cheolhee WON

IPC分类号： A61K31/713 ,  C12N15/113 ,  A61P35/00

摘要： The present invention provides siRNA or dsRNA, which can effectively inhibit the expression of three highly expressed markers in liver cancer, and a pharmaceutical composition including the same can obtain excellent effects of preventing or treating liver cancer through RNAi. A pharmaceutical composition for preventing or treating liver cancer according to an embodiment of the present invention includes at least one of siRNA which includes a sense RNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 5 to 157, and an antisense RNA having a complementary sequence thereto and dsRNA having at least one sequence selected from the group consisting of sequences of SEQ ID NOs: 158 to 310.

公开(公告)号：US11793757B2

公开(公告)日：2023-10-24

申请号：US17399320

申请日：2021-08-11

申请人： LEMONEX INC.

发明人： Cheolhee Won

IPC分类号： A61K9/16 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/17 ,  A61K38/46 ,  A61K39/395

CPC分类号： A61K9/1611 ,  A61K31/203 ,  A61K31/44 ,  A61K31/4745 ,  A61K31/704 ,  A61K31/711 ,  A61K31/713 ,  A61K38/1758 ,  A61K38/465 ,  A61K39/395

摘要： A porous silica particles according to an embodiment of the present disclosure includes a plurality of pores with a diameter of 5 nm to 100 nm. The porous silica particles have particular physical properties, can deliver all various drugs by a supported amount in a sustained manner, and can be parenterally administered.

公开(公告)号：US11786469B2

公开(公告)日：2023-10-17

申请号：US15328121

申请日：2015-03-31

申请人： LEMONEX INC. ,  Cheolhee Won

发明人： Cheolhee Won

IPC分类号： A61K9/14 ,  A61K47/02 ,  A61K39/395 ,  A61K47/40 ,  A61K9/16 ,  B82Y5/00

CPC分类号： A61K9/143 ,  A61K9/145 ,  A61K9/16 ,  A61K39/395 ,  A61K47/02 ,  A61K47/40 ,  B82Y5/00

摘要： A composition for delivering a bioactive material include a porous silica nanoparticle containing pores with an average pore diameter ranging from 1 nm to 100 nm, at least one of (i) a functional group which binds to the pore surface of the porous silica nanoparticle and gives the pore surface a negative charge or a positive charge, (ii) a ligand which binds to the pore surface of the porous silica nanoparticle and specifically binds to the bioactive material, and (iii) a combination of the functional group and the ligand, and a bioactive material having a size to be accommodated within the pores of the porous silica nanoparticle, the bioactive material bound to said at least one of the functional group and the ligand bound to the pore surface of the mesoporous silica nanoparticle and accommodated within the pores of the porous silica nanoparticle.

公开(公告)号：US20220143068A1

公开(公告)日：2022-05-12

申请号：US17533533

申请日：2021-11-23

申请人： LEMONEX INC.

发明人： Cheol Hee WON ,  Jun KIM

IPC分类号： A61K31/7105 ,  A61K31/713 ,  A61K47/69 ,  A61P35/00

摘要： A nucleic acid carrier according to an embodiment of the present disclosure includes CpG-ODN-RNA conjugate and a porous silica particle carrying the conjugate inside pores thereof. In this regard, the nucleic acid carrier of the present invention can stably deliver loaded nucleic acid molecules to a body and release the same to a target, thereby increasing Type 1 interferon and exhibiting RNA-inherent functions.

公开(公告)号：US20210137922A1

公开(公告)日：2021-05-13

申请号：US16476220

申请日：2018-01-08

申请人： LEMONEX INC.

发明人： Jae Ho LEE ,  Dal-Hee MIN ,  Cheolhee WON

IPC分类号： A61K31/506 ,  A23L33/10 ,  A61K31/337 ,  A61K31/475 ,  A61K31/165 ,  A61K31/343 ,  A61K33/243 ,  A61P35/04

摘要： A method for treatment of cancer selected from the group consisting of metastatic ovarian cancer, endometrial cancer, and breast cancer includes administering a composition comprising a compound represented by Formula 1, a pharmaceutically acceptable salt thereof to a subject in need thereof: The composition can efficiently kill cancer cells present in a spheroid form, thereby being usefully applied as novel medicament for metastatic ovarian cancer, endometrial cancer or breast cancer.

公开(公告)号：US20220110964A1

公开(公告)日：2022-04-14

申请号：US17265386

申请日：2019-08-01

申请人： LEMONEX INC.

发明人： Cheol Hee WON

IPC分类号： A61K31/7088 ,  A61K9/14 ,  C12N15/113

摘要： A composition according to an embodiment includes porous silica particles carrying nucleic acid molecules that complementarily bind to at least a portion of thymic stromal lymphopoietin (TSLP) mRNA. The composition is capable of preventing or treating, with excellent efficiency, atopic diseases, such as bronchial asthma, allergic rhinitis, atopic dermatitis, allergic dermatitis or inflammatory skin diseases by effectively inhibiting the expression level of TSLP.

公开(公告)号：US20210230602A1

公开(公告)日：2021-07-29

申请号：US17162045

申请日：2021-01-29

申请人： LEMONEX INC.

发明人： Cheol Hee WON

IPC分类号： C12N15/113 ,  A61K9/16 ,  C07K14/00 ,  A61P17/02

摘要： A composition according to an embodiment of the present invention includes nucleic acid molecules which are capable of effectively inhibiting the expression level of connective tissue growth factor (CTGF) and collagen by RNA interference (RNAi), thereby preventing or treating a variety of fibroproliferative diseases due to overexpression of CTGF or collagen.

公开(公告)号：US20210228670A1

公开(公告)日：2021-07-29

申请号：US17258312

申请日：2019-07-09

申请人： LEMONEX INC.

发明人： Cheol Hee WON ,  Jun KIM

IPC分类号： A61K36/61 ,  A23L33/105 ,  A61K9/00 ,  A61P27/02

摘要： A composition according to an embodiment of the present disclosure includes a banaba leaf extract, a guava leaf extract or a mixture thereof. The composition inhibits photooxidation of A2E due to blue light, inhibits a death of retinal pigment epithelial cells induced by blue light, and inhibits a damage to outer nuclear layers of visual cells in an animal model with blue light-induced macular degeneration, and thus can be beneficially used as a composition for preventing or treating macular degeneration and as a health functional food for preventing or alleviating macular degeneration.